Trial shows Vascazen (Pivotal Therapeutics) effective in altering cholesterol levels in patients with CV Risk

A trial has demonstrated that Vascazen (omega-3 oil), from Pivotal Therapeutics, is highly effective in correcting an omega-3 deficiency. The company suggests this could have benefits for people at risk of developing CardioVascular Disease. In eight weeks of treatment a statistically significant (p<0.0001) increase of 121% in the omega-score and 112% (p><0.0001) in omega-index (the blood levels of epa, dha and dpa) was observed in vascazen treated subjects.>

The Vascazen-REVEAL trial confirms Pivotal's open label study results conducted in 2011 that identified >80% of CVD patients as Omega-3 deficient. The median placebo adjusted reduction in triglycerides in the Vascazen treatment group was 48%. This reduction was statistically significant (p<0.0005). the vascazen treated group showed vldl cholesterol reduction of 30% (p="0.0023)" and hdl-c increase of 9% (p="0.0069)" without significantly affecting ldl-c, apob or hscrp levels. the safety profile of vascazen was similar to placebo. results were presented at the american heart association's arteriosclerosis, thrombosis and vascular biology meeting.>